Yixintang Pharmaceutical Group Co (SZSE:002727) EBIT : ¥844 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Yixintang Pharmaceutical Group Co EBIT?

Yixintang Pharmaceutical Group Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥321 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥844 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Yixintang Pharmaceutical Group Co's annualized ROC % for the quarter that ended in Mar. 2024 was 14.38%. Yixintang Pharmaceutical Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 32.04%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Yixintang Pharmaceutical Group Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 7.27%.

Yixintang Pharmaceutical Group Co EBIT Historical Data

The historical data trend for Yixintang Pharmaceutical Group Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yixintang Pharmaceutical Group Co EBIT Chart

Yixintang Pharmaceutical Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

782.76

981.43

1,232.74

1,382.10

837.90

Yixintang Pharmaceutical Group Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															315.04	313.18	249.13	-39.45	321.33

Competitive Comparison of Yixintang Pharmaceutical Group Co's EBIT

For the Pharmaceutical Retailers subindustry, Yixintang Pharmaceutical Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yixintang Pharmaceutical Group Co's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Yixintang Pharmaceutical Group Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Yixintang Pharmaceutical Group Co's EV-to-EBIT falls into.

Yixintang Pharmaceutical Group Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥844 Mil.

Yixintang Pharmaceutical Group Co (SZSE:002727) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Yixintang Pharmaceutical Group Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	1426.076 * ( 1 - 13.77% )	/	( (8454.934	+	8653.417)	/ 2 )
=	1229.7053348	/	8554.1755
=	14.38 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	16647.375	-	5499.277	-	( 3675.634	-	max(0, 7199.722	-	9892.886	+	3675.634	))
=	8454.934

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	17540.628	-	6110.688	-	( 3905.883	-	max(0, 7769.089	-	10545.612	+	3905.883	))
=	8653.417

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Yixintang Pharmaceutical Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	1285.328	/	( ( (3951.118 + max(61.450000000002, 0))	+	(4010.219 + max(-53.659000000001, 0)) )	/	2 )
=	1285.328	/	( ( 4012.568	+	4010.219 )	/	2 )
=	1285.328	/	4011.3935
=	32.04 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1436.843	+	3852.556	+	525.494)	-	(5499.277	+	0	+	254.166)
=	61.450000000002

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1963.865	+	3966.085	+	267.718)	-	(6110.688	+	0	+	140.639)
=	-53.659000000001

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Yixintang Pharmaceutical Group Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	844.194	/	11605.591
	=	7.27 %

Yixintang Pharmaceutical Group Co EBIT Related Terms

Thank you for viewing the detailed overview of Yixintang Pharmaceutical Group Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Yixintang Pharmaceutical Group Co (SZSE:002727) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Yixintang Pharmaceutical Group Co Ltd (SZSE:002727) » Definitions » EBIT

Traded in Other Exchanges

N/A

Address

No. 1 Hongxiang Road, Economic Development Zone, Yunnan province, Kunming City, CHN, 650500

Website

http://www.hx8886.com

Yixintang Pharmaceutical Group Co Ltd is a China-based company engages in the operation of pharmaceutical retail chains and wholesale businesses. Its products include traditional Chinese medicine, Western medicine, and medical equipment.

Executives

Zhang Yong	Directors, executives
Xiao Dong Lei	Executives
Liu Qiong	Director
Ruan Hong Xian	Directors, executives
Guo Chun Li	Director
Ruan Guo Wei	Directors, executives
Li Zheng Hong	Directors, executives
Zhao Biao	Directors, executives
Tian Jun	Directors, Directors, and Executives
Xu Ke Yi	Director
Luo Yong Bin	Executives
Zhou Hong Yun	Directors, executives

Yixintang Pharmaceutical Group Co (SZSE:002727) Headlines

No Headlines